BACKGROUND: Neuroendocrine differentiation has been demonstrated by immunohistochemical preparations in many cases of acinar type prostatic adenocarcinoma (CAP). Some studies have suggested that this differentiation may indicate an adverse prognosis. METHODS: Tissue samples from 38 consecutive patients with clinical Stage II (AJCC) CAP who underwent radical retropubic prostatectomy (RRP) were studied after preparations were made with antichromogranin (ChA) and neuron-specific enolase (NSE). All patients were followed for at least 4 years post-RRP or until disease progression was documented by rising serum prostate specific antigen concentration, X-ray evidence of recurrence, or a positive tissue biopsy. RESULTS: Nine of the 38 RRP specimens (24%) were positive for NSE, and 11 (29%) were positive for ChA. Neither of these neuroendocrine markers showed a significant correlation with tumor progression. Neuroendocrine differentiation in needle biopsy specimens from these same patients (when available) did not correlate with tumor progression either. Of the patients with tumor progression, 9 of 11 (82%) had pathologic Stage III disease after RRP; of those with no progression of CAP, only 7 of 27 (26%) had pathologic Stage III disease. CONCLUSIONS: Neuroendocrine differentiation, as demonstrated by NSE and ChA preparations, was not helpful in predicting tumor progression of CAP.
BACKGROUND: Neuroendocrine differentiation has been demonstrated by immunohistochemical preparations in many cases of acinar type prostatic adenocarcinoma (CAP). Some studies have suggested that this differentiation may indicate an adverse prognosis. METHODS: Tissue samples from 38 consecutive patients with clinical Stage II (AJCC) CAP who underwent radical retropubic prostatectomy (RRP) were studied after preparations were made with antichromogranin (ChA) and neuron-specific enolase (NSE). All patients were followed for at least 4 years post-RRP or until disease progression was documented by rising serum prostate specific antigen concentration, X-ray evidence of recurrence, or a positive tissue biopsy. RESULTS: Nine of the 38 RRP specimens (24%) were positive for NSE, and 11 (29%) were positive for ChA. Neither of these neuroendocrine markers showed a significant correlation with tumor progression. Neuroendocrine differentiation in needle biopsy specimens from these same patients (when available) did not correlate with tumor progression either. Of the patients with tumor progression, 9 of 11 (82%) had pathologic Stage III disease after RRP; of those with no progression of CAP, only 7 of 27 (26%) had pathologic Stage III disease. CONCLUSIONS: Neuroendocrine differentiation, as demonstrated by NSE and ChA preparations, was not helpful in predicting tumor progression of CAP.
Authors: Giordano Savelli; Alfredo Muni; Roberta Falchi; Alberto Zaniboni; Roberto Barbieri; Giuseppe Valmadre; Chiara Minari; Camilla Casi; Pierluigi Rossini Journal: Ann Transl Med Date: 2015-06
Authors: J Jongsma; M H Oomen; M A Noordzij; W M Van Weerden; G J Martens; T H van der Kwast; F H Schröder; G J van Steenbrugge Journal: Am J Pathol Date: 1999-02 Impact factor: 4.307
Authors: M A Noordzij; W M van Weerden; C M de Ridder; T H van der Kwast; F H Schröder; G J van Steenbrugge Journal: Am J Pathol Date: 1996-09 Impact factor: 4.307
Authors: David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng Journal: Endocr Pathol Date: 2016-06 Impact factor: 3.943
Authors: Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger Journal: Nat Rev Urol Date: 2014-02-18 Impact factor: 14.432
Authors: Jonathan I Epstein; Mahul B Amin; Himisha Beltran; Tamara L Lotan; Juan-Miguel Mosquera; Victor E Reuter; Brian D Robinson; Patricia Troncoso; Mark A Rubin Journal: Am J Surg Pathol Date: 2014-06 Impact factor: 6.394
Authors: Harsimar Kaur; Iryna Samarska; Jiayun Lu; Farzana Faisal; Benjamin L Maughan; Sanjana Murali; Kaushal Asrani; Mohamed Alshalalfa; Emmanuel S Antonarakis; Jonathan I Epstein; Corinne E Joshu; Edward M Schaeffer; Juan Miguel Mosquera; Tamara L Lotan Journal: Prostate Date: 2020-07-10 Impact factor: 4.012